Metagenomi

Metagenomi is a precision genetic medicines company that utilizes an AI-integrated metagenomics discovery engine to identify and develop next-generation genome editing tools. By 2026, the company has solidified its position in the market by moving beyond standard CRISPR-Cas9 limitations, offering a proprietary library of billions of microbial genomes. Their technical architecture involves high-throughput screening of non-culturable organisms combined with deep learning models that predict the structural and functional properties of novel nucleases. This allows for the discovery of ultra-compact editors capable of being delivered via highly efficient vectors like AAV or LNPs. Metagenomi's platform acts as a vertically integrated R&D stack, providing partners with modular components for base editing, prime editing, and large-scale genome integration. In the 2026 landscape, Metagenomi serves as a critical infrastructure layer for pharmaceutical companies looking to bypass existing patent thickets while achieving higher specificity and lower off-target profiles in therapeutic applications.